Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2024 08:00 ET | Source: Straits Research

Global Urinary Tract Infection Market Size is Projected to Reach USD 11.85 billion by 2031, Growing at a CAGR of 3.2%: Straits Research

New York, United States, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Urinary tract infections affect the kidneys, ureters, bladder, or urethra (UTI). The development of novel urinary incontinence devices, the...
January 24, 2023 09:03 ET | Source: Research Dive

Global Urinary Tract Infection Testing Market Projected to Generate a Revenue of $1,027.4 Million and Rise at a CAGR of 6.2% during the Analysis Period 2022-2031 [240-Pages] | Details by Research Dive

New York, USA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Urinary Tract Infection Testing Market by Infection Type (Urethritis, Cystitis,...
August 30, 2022 08:33 ET | Source: Research and Markets

Outlook on the Urinary Tract Infection Testing Global Market to 2030 - Featuring Accelerate Diagnostics, Bio-Rad Laboratories and Danaher Among Others

Dublin, Aug. 30, 2022 (GLOBE NEWSWIRE) -- The "Global Urinary Tract Infection Testing Market Size, Share & Trends Analysis by Type (Urethritis, Cystitis, Pyelonephritis), by End-Use (Reference...
October 29, 2021 13:45 ET | Source: The Insight Partners

Hematuria Treatment Market Size ($1,103.61Mn by 2028) Led by Urinary Tract Infections (17.31% Market Share in 2020) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com

New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Hematuria Treatment Market: Key InsightsAccording to our new research study on Hematuria Treatment Market Size and Forecast to 2028 - COVID-19 Impact and...
November 09, 2016 07:30 ET | Source: Cempra, Inc.

Cempra to Present at Two Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
November 01, 2016 07:30 ET | Source: Cempra, Inc.

Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan

CHAPEL HILL, N.C., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 27, 2016 16:15 ET | Source: Cempra, Inc.

Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update

CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 25, 2016 16:15 ET | Source: Cempra, Inc.

Cempra to Report Third Quarter 2016 Financial Results

CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 04, 2016 16:15 ET | Source: Cempra, Inc.

Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting

—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately one of four elderly patients— —Average U.S. macrolide resistance to S. pneumoniae...
September 29, 2016 16:15 ET | Source: Cempra, Inc.

Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study

— Pre/post treatment biopsies confirm mean NAS reduction of 1.3 points after 90 days of treatment with solithromycin — — All six patients showed ALT reductions after 90 days of treatment with...

Next Page keyboard_arrow_right